Literature DB >> 20231407

Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.

Aoife M Roche1, Jeffrey N Weiser.   

Abstract

Much of the efficacy of current pneumococcal conjugate vaccines lies in their ability to decrease carriage of vaccine serotypes in the population. Novel and more-broadly acting vaccines would also need to target carriage in order to be as effective. We have previously shown that model murine carriage of Streptococcus pneumoniae can elicit antibody-dependent immunity and can protect against a virulent heterologous challenge strain. This study set out to identify S. pneumoniae surface antigens that may elicit cross-reactive antibodies following colonization. Western blot analysis using sera from colonized mice identified the previously characterized immunogens pneumococcal surface protein A (PspA), putative proteinase maturation protein A (PpmA), and pneumococcal surface adhesin A (PsaA) as such antigens. Using flow cytometry, PspA was found to be the major target of surface-bound cross-reactive IgG in sera from TIGR4 Delta cps-colonized mice, with a modest contribution from PpmA and none from PsaA. In human sera, however, only mutants lacking PpmA were shown to have reduced binding of surface IgG compared to wild-type strains, suggesting that prior exposure to S. pneumoniae in humans may induce PpmA antibodies. We also investigated if cross-reactive antibodies induced by these antigens may be cross-protective against carriage. Despite the immunogenicity of PspA, PpmA, and PsaA, mice were still protected following colonization with mutants lacking these antigens, suggesting they are not necessary for cross-protection induced by carriage. Our findings suggest that a whole-organism approach may be needed to broadly diminish carriage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231407      PMCID: PMC2863509          DOI: 10.1128/IAI.01058-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Complete genome sequence of a virulent isolate of Streptococcus pneumoniae.

Authors:  H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser
Journal:  Science       Date:  2001-07-20       Impact factor: 47.728

7.  Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.

Authors:  Dennis O Gor; Xuedong Ding; David E Briles; Michael R Jacobs; Neil S Greenspan
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.

Authors:  Aaron L Nelson; Aoife M Roche; Jane M Gould; Kannie Chim; Adam J Ratner; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

9.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

View more
  12 in total

Review 1.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

2.  The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Authors:  Kosuke Kataoka; Kohtaro Fujihashi; Keita Oma; Yoshiko Fukuyama; Susan K Hollingshead; Shinichi Sekine; Shigetada Kawabata; Hiro-O Ito; David E Briles; Kazunori Oishi
Journal:  Infect Immun       Date:  2011-05-02       Impact factor: 3.441

3.  Influence of age, social patterns and nasopharyngeal carriage on antibodies to three conserved pneumococcal surface proteins (PhtD, PcpA and PrtA) in healthy young children.

Authors:  A Hagerman; K M Posfay-Barbe; S Grillet; M M Ochs; R H Brookes; D Greenberg; N Givon-Lavi; R Dagan; C-A Siegrist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-18       Impact factor: 3.267

Review 4.  The role of bacterial protein tyrosine phosphatases in the regulation of the biosynthesis of secreted polysaccharides.

Authors:  Alistair J Standish; Renato Morona
Journal:  Antioxid Redox Signal       Date:  2014-03-11       Impact factor: 8.401

5.  Streptococcus pneumoniae Colonization Is Required To Alter the Nasal Microbiota in Cigarette Smoke-Exposed Mice.

Authors:  Pamela Shen; Fiona J Whelan; L Patrick Schenck; Joshua J C McGrath; Gilles Vanderstocken; Dawn M E Bowdish; Michael G Surette; Martin R Stämpfli
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

6.  Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation.

Authors:  Jonathan M Cohen; Suneeta Khandavilli; Emilie Camberlein; Catherine Hyams; Helen E Baxendale; Jeremy S Brown
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

7.  Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses.

Authors:  R Wilson; J M Cohen; R J Jose; C de Vogel; H Baxendale; J S Brown
Journal:  Mucosal Immunol       Date:  2014-10-29       Impact factor: 7.313

8.  Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study.

Authors:  P Turner; C Turner; N Green; L Ashton; E Lwe; A Jankhot; N P Day; N J White; F Nosten; D Goldblatt
Journal:  Clin Microbiol Infect       Date:  2013-12       Impact factor: 8.067

9.  Streptococcus pneumoniae Transmission Is Blocked by Type-Specific Immunity in an Infant Mouse Model.

Authors:  Tonia Zangari; Yang Wang; Jeffrey N Weiser
Journal:  mBio       Date:  2017-03-14       Impact factor: 7.867

10.  Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice.

Authors:  Sang-Yoon Choi; Thao Dang-Hien Tran; David E Briles; Dong-Kwon Rhee
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.